Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Scoop Today USA journalist was involved in the writing and production of this article.
Neuralia TMS Expands Access to Innovative OCD Treatment in Australia
Australia, 21st Feb 2025, – Neuralia TMS has announced an expansion of its services to enhance access to transcranial magnetic stimulation (TMS) therapy for individuals living with obsessive-compulsive disorder (OCD) in Australia. This initiative aims to provide additional treatment options for those seeking alternatives to traditional therapies.
OCD is a chronic mental health disorder characterised by persistent thoughts (obsessions) and repetitive behaviours (compulsions). Standard treatment options include cognitive-behavioural therapy and medication, though these approaches may not be effective for all individuals. TMS therapy has been studied as a potential option, with research exploring its impact on reducing OCD symptoms through brain activity modulation.
Neuralia TMS has expanded its facilities and treatment availability to ensure that more patients can access TMS therapy. This expansion includes the addition of new treatment locations and the introduction of specialised protocols designed for OCD management.
“Many individuals struggling with OCD find that traditional treatments do not provide adequate relief,” said Dr. Shanek Wick, medical director of Neuralia TMS. “By increasing access to TMS therapy, more patients will have the opportunity to explore an evidence-based, non-invasive option that may help alleviate their symptoms.”
TMS therapy involves the use of magnetic pulses to target specific brain regions associated with OCD. Unlike medications, TMS does not involve systemic side effects, making it an alternative for individuals who have not responded to conventional pharmacological treatments.
In addition to TMS, Neuralia TMS provides transcranial direct current stimulation (tDCS), an at-home neuromodulation therapy that is being investigated as a complementary approach for managing symptoms. The organisation also incorporates pharmacogenetic testing to tailor treatment strategies based on genetic factors.
The expansion efforts include collaboration with healthcare providers with healthcare providers to raise awareness of TMS therapy and ensure that more patients are informed about available treatment options. Neuralia TMS will provide educational resources for mental health professionals on the latest research and clinical applications of TMS in OCD treatment.
The organisation is also engaged in ongoing research initiatives to refine neuromodulation protocols and improve treatment efficacy. Future developments may contribute to a broader understanding of how TMS can be applied across various psychiatric and neurological conditions.
“The future of mental health treatment lies in ongoing research and accessibility,” Dr. Wick added. “Collaboration with the medical community and continuous advancements in technology will be essential in improving patient outcomes and expanding options for those facing treatment-resistant conditions.”
Neuralia TMS remains focused on contributing to the field of mental health by supporting scientific exploration and improving access to potential treatment methods for individuals with OCD and other neurological conditions.
For more information about OCD treatment Australia, please contact Neuralia TMS. The company can be reached by phone at 08 6230 3996 or via email at info@neuralia.com.au.
Media Contact
Organization: Neuralia TMS
Contact
Person: Dr Shanek Wick
Website:
https://www.neuraliatms.com.au/
Email:
info@neuralia.com.au
Contact Number: 61862303996
Country:Australia
The post Neuralia TMS Expands Access to Innovative OCD Treatment in Australia appeared first on
Brand News 24.
It is provided by a third-party content
provider. Brand News 24 makes no
warranties or representations in connection with it.
